Tax Matters (Deferred Taxes) (Details) - USD ($) $ in Millions		Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2020		Dec. 31, 2019
Taxes on Income [Line Items]
Unrecognized Tax Benefits		$ 194	[1]	$ 189	[1]	$ 188	[1]	$ 182
Prepaid/deferred items		192		109
Inventories		22
Inventories				(10)
Capitalized R&D for tax		111		0
Identifiable intangible assets		(154)		(187)
Property, plant and equipment		(204)		(183)
Employee benefits		61		58
Restructuring and other charges		1		3
Legal and product liability reserves		14		14
Net operating loss/credit carryforwards		112		132
Unremitted earnings		(4)		(7)
All other		9
All other				5
Subtotal		160		(46)
Valuation allowance		(129)		(174)
Deferred Tax Assets, Net	[2],[3]	31
Net deferred income tax liability	[2],[3]			(220)
Noncurrent deferred tax assets		173		100
Noncurrent deferred tax liabilities		142		320
Cumulative amount of undistributed earnings		7,400
Noncurrent Deferred Tax Assets
Taxes on Income [Line Items]
Unrecognized Tax Benefits		2		1		1
Other Taxes Payable
Taxes on Income [Line Items]
Unrecognized Tax Benefits		$ 192		$ 188		$ 187

[1] In 2022, included in Noncurrent deferred tax assets and Other noncurrent assets ($2 million) and Other taxes payable ($192 million). In 2021, included in Noncurrent deferred tax assets and Other noncurrent assets ($1 million) and Other taxes payable ($188 million). In 2020, included in Noncurrent deferred tax assets and Other noncurrent assets ($1 million) and Other taxes payable ($187 million).

[2] In 2022, included in Noncurrent deferred tax assets ($173 million) and Noncurrent deferred tax liabilities ($142 million). In 2021, included in Noncurrent deferred tax assets ($100 million) and Noncurrent deferred tax liabilities ($320 million).

[3] The change in the total net deferred tax asset/(liability) from December 31, 2021 to December 31, 2022 is primarily attributable to an increase in deferred tax assets related to prepaid/deferred items as a result of a prepayment from a related foreign entity in Belgium and an increase in deferred tax assets related to the capitalization and amortization of research & development costs for U.S. tax purposes.